Jan 11 (Reuters) - NANOBIOTIX SA:
* NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS
* COLLABORATION WILL TAKE PLACE OVER COURSE OF ONE YEAR * WILL LAUNCH ITS FIRST CLINICAL TRIAL COMBINING NBTXR3 WITH IMMUNE CHECKPOINT INHIBITORS IN U.S.
* HAS RECEIVED APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND Source text for Eikon: Further company coverage: (Gdynia Newsroom)
Our Standards: The Thomson Reuters Trust Principles.